Genen­tech touts pos­i­tive Phase III da­ta for Tecen­triq/Avastin com­bo in liv­er can­cer

The Tecen­triq and Avastin com­bi­na­tion met its pri­ma­ry end­point — re­cur­rence-free sur­vival — for peo­ple with liv­er can­cer, specif­i­cal­ly ear­ly-stage he­pa­to­cel­lu­lar car­ci­no­ma, in a Phase III study, Genen­tech an­nounced Thurs­day.

The in­ter­im analy­sis of the Phase III IM­brave050 study showed “sta­tis­ti­cal­ly sig­nif­i­cant” im­prove­ment in their tar­get pa­tients: peo­ple who have a high risk of the dis­ease re­turn­ing af­ter they’ve had ab­la­tion or surgery to re­move the can­cer. This im­prove­ment was com­pared to pa­tients who on­ly had ac­tive sur­veil­lance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER